Healthcare investment company ARCHIMED’s affiliate to acquire ZimVie for $730m, focusing on dental implants. Stockholders to receive $19.00 per share, a 99% premium. ZimVie board approves, pending closing conditions. ARCHIMED excited for growth potential. ZimVie to become private entity after acquisition with support from Centerview Partners.

ZimVie CEO sees value in partnership with ARCHIMED, creating shareholder value and expanding innovative dental technology globally. Centerview Partners advises ZimVie, Cravath, Swaine & Moore legal adviser. UBS Investment Bank and Latham & Watkins assist ARCHIMED. FDA cleared ZimVie’s Vital spinal fixation system in 2023 with Brainlab tools.

Acquisition of ZimVie by ARCHIMED for $730m announced. ZimVie to focus on dental implants, with support from new partners. FDA clearance for spinal fixation system in 2023. Strong growth potential expected. Expert financial and legal advisers involved in the transaction.

Read more at Yahoo Finance: ARCHIMED to acquire life sciences company ZimVie for $730m